Investment in Altair

RNS Number : 1843U
Intuitive Investments Group plc
31 March 2021
 


31 March 2021

Intuitive Investments Group plc

Investment in Altair Medical Ltd

Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £350,000 to acquire new ordinary shares in Altair Medical Ltd ("Altair"), representing a 6.55 per cent. interest in Altair's enlarged share capital, as part of a £2 million fundraising round.

 

Altair, which was incorporated in February 2018,  is developing an innovative remote respiratory monitoring platform comprising a small, chest-worn biosensor and AI-driven data analysis/alerting software for the early detection, prediction and prevention of adverse events in respiratory patients, both in hospitals and at home. In 2020, Altair was awarded the Breakthrough Medical Device designation from the U.S. Food and Drug Administration for the development of the device, which is designed to monitor breathing in real-time to a clinical standard of care1.  

 

The specially designed wireless biosensor is one of the smallest available, and transmits data to the cloud using a data hub or smartphone, alerting the patient, their household members, doctor, nurse or emergency services where life-threatening changes occur. Altair's technology will be able to accurately monitor large numbers of patients in any location at any time. Additional information relating to Altair can be found at: https://www.altairmedical.com/home.html.

 

Altair, per the company's accounts, achieved a loss after tax for the 12 months ended 30 April 2020 of £110,800 and, as at 30 April 2020, had net liabilities of £171,843.

 

Stewart White, Chairman of IIG's Advisory Panel, will be appointed as non-executive director of Altair.

 

 

Notes:-

1 - performance characteristics are yet to be clinically validated.

For further information, please contact:

Intuitive Investments Group plc

www.iigplc.com

David Evans, Executive Chairman

Robert Naylor, CEO

Via Walbrook PR

 

 

Strand Hanson Limited - Nominated Adviser

+44 (0) 20 7409 3494

James Harris / James Dance / James Bellman

 

 

 





Turner Pope Investments (TPI) Ltd - Broker

+44 (0) 20 3657 0050

Andrew Thacker / Zoe Alexander

 

 

 

Walbrook PR Limited - Media & Investor Relations

+44 (0)20 7933 8780 or intuitive@walbrookpr.com

Sam Allen / Paul McManus

+44 (0)7502 558 258 / +44 (0) 7980 541 893

 

 

About Intuitive Investments Group plc

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCJBMATMTBJBFB
UK 100

Latest directors dealings